NDRG1 and cancer: Anti-cancer agents of the di-2-pyridylketone thiosemicarbazone class e.g., di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone (Dp44mT), clinically trialed di-2-pyridylketone-4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), and (E)-3-phenyl-1-(2-pyridinyl)-2-propen-1-one 4,4-dimethyl-3-thiosemicarbazone (PPP44mT) have demonstrated activity to upregulate NDRG1 in cancer cells (9, 14, 15, 16, 17, 18, 34, 35, 36, 37, 38, 39, 40, 41, 42) with this class of agents being under development as anti-cancer drugs (74).